iPsomics is a life science start-up developing iPSC-based disease models and single-cell diagnostics to advance drug discovery and personalized cancer care, serving both academic and commercial partners.
Single-cell whole-genome sequencing (scWGS).
Single-cell shallow whole genome sequencing (scsWGS) – A cost-effective way to detect genetic changes at the single-cell level.
Advanced single-cell sequencing applications – Customized single-cell analysis to explore gene expression, chromatin accessibility, or epigenetic modifications.
Bulk RNA sequencing – A powerful method for analyzing gene expression in tissue or cell populations, providing insights into disease states and treatment responses.
Induced pluripotent stem cells (iPSCs) are revolutionizing biomedical research by enabling the creation of patient-specific models of diseases:
Custom iPSC generation – We generate iPSC lines tailored to researchers’ needs.
iPSC generation and acquisition from biobanks – Access to existing high-quality iPSC lines for research and therapeutic development.
CRISPR-based genome engineering– Precise genetic modifications of iPSCs to model diseases or correct genetic defects.
We create human-relevant disease models to study biological mechanisms and test drugs in realistic environments:
iPSC-derived disease models – Human cell-based models that replicate disease conditions, offering an alternative to traditional animal models.
Organ-on-a-Chip (O-o-C) platforms – Microfluidic devices that mimic the behavior of human organs, providing a powerful tool for studying disease progression and testing drugs in a physiologically relevant setting.
Drug screening on iPSC-derived disease models – Testing drug efficacy and toxicity using patient-specific or genetically modified models.
iPsomics’ CEO Peter Ketelaar and CSO Floris Foijer attended the Innovation for Health event in Rotterdam. Peter Ketelaar presented how PharmaNL made it possible to commercialize two academic facilities into a commercial business (iPsomics) thanks to the PharmaNL program.
iPsomics will attend the EMBO Chromoploidy Conference in Stresa, Italy. Our CSO Floris Foijer is co-organizer and will host the conference’s keynote speaker Prof. Rene Medema (scientific director Princess Maxima Centre for paediatric cancer research, Utrecht).
iPsomics organized its first Scientific Symposium to celebrate 6 months of iPsomics. Three leading experts, Prof. Christine Mummery (LUMC), Prof. Joost Gribnau (ErasmusMC) and Prof. Edwin Cuppen (UMC Utrecht & Hartwig Medical Foundation) discussed the latest developments in organ on a chip, induced pluripotent stem cells and whole cell sequencing technology for a large audience of UMCG scientists.
iPsomics will attend the Swiss Biotech Days in Basel in Basel, Switzerland. Our CEO Peter Ketelaar will participate in the Organ-on-a-Chip Roundtable: Implementation through collaboration between the Netherlands and Switzerland (May 6 – 12:00-12:45)
iPsomics will attend the BIO-EUROPE conference in Vienna, Austria. Floris Foijer, CSO and Peter Ketelaar, CEO will participate in the Partnering Event. We look forward to meeting you there.
Ready to transform your
research or accelerate
cancer diagnostics?
